Zheng Quan Ri Bao·2026-01-13 08:18Core Insights - The article highlights a significant milestone in the treatment of infantile hemangiomas with the launch of a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after 12 years of research [1] - Beimeijing® is the first and only topical gel approved for the treatment of "proliferative superficial infantile hemangiomas," marking a key advancement for China in this medical field [1] - The drug has received authoritative certification from the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Context - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The critical intervention period for effective treatment is within the first 1-6 months after birth, known as the "golden window," where timely treatment can prevent long-term skin issues [2] - Traditional treatment methods have faced limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - The development of Beimeijing® was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, involving a comprehensive process from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and non-invasive option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data supports the advantages of Beimeijing®, showing a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% among 121 infants aged 1-6 months, with good safety profiles [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the needs of children, ensuring that the standardized treatment approach is effectively communicated to families [3]